Skip to main content
. 2020 May 8;44(1):165–173. doi: 10.3892/or.2020.7608

Figure 2.

Figure 2.

H19 knockdown sensitizes HCC cells to sorafenib in vitro. (A) Sorafenib sensitivity of HCC cells transfected with NC siRNA or H19 siRNA. (B) Proliferative capacity of HCC cells transfected with NC siRNA or H19 siRNA and subjected to sorafenib treatment. **P<0.01, ***P<0.001, compared with the sorafenib group. (C) H19 expression in HCC cells transfected with NC siRNA or H19 siRNA and subjected to sorafenib treatment. *P<0.05, **P<0.01, ***P<0.001, compared to the control. HCC, hepatocellular carcinoma; NC, negative control.